Regulation of gene expression is an important mechanism through which genetic variation can affect complex traits. A substantial portion of gene expression variation can be explained by both local (cis) and distal (trans) genetic variation. Much progress has been made in uncovering cis-acting expression quantitative trait loci (cis-eQTL), but trans-eQTL have been more difficult to identify and replicate. Here we take advantage of our ability to predict the cis component of gene expression coupled with gene mapping methods such as PrediXcan to identify high confidence candidate trans-acting genes and their targets. That is, we correlate the cis component of gene expression with observed expression of genes in different chromosomes. Leveraging the shared cis-acting regulation across tissues, we combine the evidence of association across all available GTEx tissues and find 2356 trans-acting/target gene pairs with high mappability scores. Reassuringly, trans-acting genes are enriched in transcription and nucleic acid binding pathways and target genes are enriched in known transcription factor binding sites. Interestingly, trans-acting genes are more significantly associated with height than target or background genes, consistent with percolating trans effects. Our scripts and summary statistics are publicly available for future studies of transacting gene regulation. gene expression | trans-eQTLs | genetic prediction | complex trait genetics Correspondence: hwheeler1@luc.edu, haky@uchicago.edu Wheeler et al. | bioRχiv | November 15, 2018 | 1-10 Methods Genome and transcriptome data.
Introduction
Transcription is modulated by both proximal genetic variation (cis-acting), which likely affects DNA regulatory elements near the target gene, and distal genetic variation (transacting), which likely affects regulation of a transcription factor (or coactivator) that goes on to regulate a target gene, often located on a different chromosome from the transcription factor gene. Expression quantitative trait loci (eQTL) mapping has been successful at identifying and replicating SNPs associated with gene expression in cis, typically meaning SNPs within 1 Mb of the target gene. Because effect sizes are large enough, around 100 samples in the early eQTL studies could detect replicable associations in the reduced multiple testing space of cis-eQTLs (1) (2) (3) . trans-eQTLs have been more difficult to replicate because their effect sizes are usually smaller and the multiple testing burden for testing all SNPs versus all genes can be too large to overcome. A few studies have had some success; one, with a discovery cohort of 5311 individuals and a replication cohort of 2775 individuals, identified and replicated 103 trans-eQTLs in whole blood (4) . Unlike cis-eQTLs, trans-eQTLs are more likely to be tissue-specific, rather than shared across tissues (5) . However, even when trans-eQTLs are discovered, the mechanism by which the SNP acts is not immediately clear.
Here, we apply PrediXcan (6) and MultiXcan to map transacting genes, rather than mapping trans-eQTLs (SNPs). Our method provides directionality, that is, whether the transacting gene activates or represses its target gene. We use genome-transcriptome data sets from the Framingham Heart Study (FHS) (7) , Depression Genes and Networks (DGN) cohort (8) , and the Genotype-Tissue expression (GTEx) Project (5) . We show that our approach, called trans-PrediXcan, can identify replicable trans-acting regulator/target gene pairs. To leverage sharing of cis-eQTLs across tissues and improve our power to detect more trans-acting effects, we combine predicted expression across tissues in our trans-MulTiXcan model and show that it increases significant trans-acting gene pairs >10-fold. Pathway analysis reveals the trans-acting genes are enriched in transcription and nucleic acid binding pathways and target genes are enriched in known transcription factor binding sites, indicating that our method identifies genes of expected function. We show that trans-acting genes are more strongly associated with height than target or background genes, demonstrating that trans-acting genes likely play a key role in the biology of complex traits.
Gene expression prediction models. Elastic net (alpha = 0.5) models built using GTEx V6p genometranscriptome data from 44 tissues (16) were downloaded from http://predictdb.org/ from the GTEx-V6p-HapMap-2016-09-08.tar.gz archive.
Mappability quality control. Genes with mappability scores less than 0.8 and gene pairs with a positive crossmappability k-mer count were excluded from our analysis (17) . Gene mappability is computed as the weighted average of its exon-mappability and untranslated region (UTR)mappability, weights being proportional to the total length of exonic regions and UTRs, respectively. Mappability of a kmer is computed as 1/(number of positions k-mer maps in the genome). For exonic regions, k = 75 and for UTRs, k = 36. Cross-mappability between two genes, A and B, is defined as the number of gene A k-mers (75-mers from exons and 36-mers from UTRs) whose alignment start within exonic or untranslated regions of gene B (17) . In addition, to further guard against false positives, we retrieved RefSeq Gene Summary descriptions from the UCSC hgFixed database on 2018-10-04 and removed genes from our analyses with a summary that contained one or more of the following strings: "paralog", "pseudogene", "retro". trans-PrediXcan. In order to map trans-acting regulators of gene expression, we implemented trans-PrediXcan, which consists of two steps. First, we predict gene expression levels from genotype dosages using models trained in independent cohorts and tissues, as in PrediXcan (6) . This step gives us an estimate of genetic component of gene expression, GReX, for each gene. In the second step, for each GReX estimate, we calculate the correlation between GReX and the observed expression level of each gene located on a different chromosome. As in Matrix eQTL (18) , variables were standardized to allow fast computation of the correlation and test statistic. In the discovery phase, we predicted gene expression in the FHS cohort using each of 44 tissue models from the GTEx Project. Significance was assessed via the Benjamini-Hochberg false discovery rate (FDR) method (19) , with FDR < 0.05 in each individual tissue declared significant. We tested discovered trans-acting/target gene pairs for replication in the DGN cohort and declared those with P<0.05 validated. To estimate the expected true positive rate, we calculate π 1 statistics using the qvalue method (20, 21) . π 1 is the expected true positive rate and was estimated by selecting the gene pairs with FDR < 0.05 in FHS and examining their P value distribution in DGN. π 0 is the proportion of false positives estimated by assuming a uniform distribution of null P values and π 1 = 1 − π 0 (21) . For comparison to our trans-PrediXcan method, we performed traditional trans-eQTL analysis in FHS and DGN using Matrix eQTL (18) , where trans is defined as genes on different chromosomes from each SNP.
trans-MulTiXcan.
To determine if jointly modeling the genetic component of gene expression across tissues would increase power to detect trans-acting regulators, we applied MulTiXcan (22) to our transcriptome cohorts. In our implementation of MulTiXcan, predicted expression from all available GTEx tissue models (up to 44) were used as explanatory variables. To avoid multicolinearity, we use the first k principal components of the predicted expression in our regression model for association with observed (target) gene expression. We keep the first k principal components out of i principal components estimated where
where λ i is an eigenvalue in the predicted expression covariance matrix (22) . We used an F-test to quantify the significance of the joint fit. We tested trans-acting/target gene pairs discovered in FHS (FDR < 0.05) for replication in the DGN cohort and declared those with P < 0.05 validated. Fig. 1 . trans-PrediXcan model. mRNA expression levels are predicted from cis region eQTLs as in PrediXcan. These predicted expression levels (trans-acting genes) are tested for association with observed expression on different chromosomes (target genes).
were 565 trans-acting genes (FHS FDR < 0.05), 694 target genes (FHS FDR < 0.05), and 9894 background genes. In UK Biobank, there were 566 trans-acting, 697 target, and 9923 background genes.
Results
Trans-acting gene discovery and validation with trans-PrediXcan. We sought to map trans-acting and target gene pairs by applying the PrediXcan framework to observed expression as traits and term the approach trans-PrediXcan ( Fig. 1 ). We excluded genes with poor genome mappability from our analyses (see Methods). We compared trans-PrediXcan results between the discovery FHS whole blood cohort (n = 4838) and the validation DGN whole blood cohort (n = 922). We first used PrediXcan (6) to generate a matrix of predicted gene expression from FHS genotypes using prediction models built in GTEx whole blood (16) . Then, we calculated the correlation between predicted and observed FHS whole blood gene expression. Examining the correlations of gene pairs on different chromosomes, 55 pairs were significantly correlated in FHS, with an expected true positive rate (π 1 ) of 0.72 in DGN (Table 1) . Gene pair information and summary statistics are shown in S1 Table. Note that the directions of effect of these 55 pairs discovered in FHS are largely consistent in DGN (Fig. 2) .
To compare the performance of our trans-PrediXcan approach to traditional trans-eQTL analysis, we also examined the P-value distribution of top FHS trans-eQTLs (FDR < 0.05) in DGN to determine the expected true positive rate. In our SNP-level trans-eQTL analysis, π 1 was 0.46, 36% lower than the trans-PrediXcan π 1 of 0.72. We also compared our results to a traditional eQTL study in an independent cohort (4) of similar size to FHS. Of the unique target genes we iden- tified in FHS, 3 (7.7%) were also target genes of trans-eQTLs (FDR < 0.05) in Westra et al.(4) . This is 2.8-fold more than expected by chance as just 2.8% of all genes tested in FHS were trans-eQTL targets in Westra et al. (4) .
Multi-tissue prediction improves trans-acting gene discovery and validation.
To leverage tissue sharing of cis-eQTLs, we used a multivariable regression approach called MulTiXcan, which accounts for correlation among predicted expression levels across 44 GTEx tissues (22) . Notice that even though we seek to detect trans regulation, the instruments we are using, i.e. predicted expression, are based on cis regulation. Thus it makes sense to combine information across tissues to obtain the best local predictor of gene expression. To address multicolinearity issues, MulTi-Xcan uses principal component analysis to reduce the number of independent variables to those with the largest variation (22) . When we applied trans-MulTiXcan to the FHS data, the number of trans-acting/target gene pairs increased dramatically ( Fig. 3 ). At FDR < 0.05, there were 2,356 trans-acting gene pairs discovered in FHS using the multitissue method, while only 55 pairs were discovered with the GTEx whole blood predictors alone (Table 1) . We could test 1,902 of these multi-tissue gene pairs for replication in DGN and found 535 of them were significant at P < 0.05 (blue in Fig. 4 ). Although the expected true positive rate was lower with the MulTiXcan model (π 1 = 0.49) than with the single tissue model (π 1 = 0.72), the absolute number of replicate gene pairs was much higher (Table 1) . Thus, the number of genes that replicated in both cohorts was 20 times higher in the multi-tissue model compared to the whole blood model ( Master trans-acting genes associate with many targets. Points that form vertical lines in Figure 4 are indicative of potential master regulators, i.e. genes that regulate many downstream target genes. We defined master regulators as trans-acting genes that associate with 50 or more target genes. In our MulTiXcan analysis, we discovered three potential master regulator loci, which are labeled in Figure 4 . The most likely master regulator we identified with MulTiX- can is ARHGEF3 on chromosome 3. ARHGEF3 associated with 53 target genes in FHS (FDR < 0.05) and 45/51 tested replicated in DGN (P < 0.05). Also, SNPs in ARHGEF3 have previously been identified as trans-eQTLs with multiple target genes. ARHGEF3 encodes a ubiquitously expressed guanine nucleotide exchange factor. Multiple GWAS and functional studies in model organisms have implicated the gene in platelet formation (27) (28) (29) (30) (31) . Similarly, SNPs at the chromosome 17 locus we identified have also been identified as trans-eQTLs (32) and one study showed the the trans effects are mediated by cis effects on AP2B1 expression (30) . AP2B1 encodes a subunit of the adaptor protein complex 2 and GWAS have implicated it in red blood cell and platelet traits (31) .
trans-acting genes are enriched in transcription factor pathways. We tested validated trans-acting genes for enrichment in Reactome (MSigDB v6.1 c2), Gene Ontology (GO, MSigDB v6.1 c5), transcription factor targets (MSigDB v6.1 c3), and GWAS Catalog (e91_r2018-02-06) pathways using FUMA (23) . In our MulTiXcan analysis, there were 174 unique trans-acting genes at FDR < 0.05 in FHS and P < 0.05 in DGN (S2 Table) . We required at least 5 trans-acting genes to overlap with each tested pathway. The background gene set used in the enrichment test were the 15,432 genes with a MulTiXcan model. All pathways with FDR < 0.05 are shown in Table 2 and their gene overlap lists are available in S4 Table. The top two most significant pathways were the GO nucleic acid binding transcription factor activity pathway and the reactome generic transcription pathway ( Table 2 ). The transacting genes in each pathway are spread across multiple chromosomes as shown in S1 Figure. PLAGL1, which encodes a C2H2 zinc finger protein that functions as a suppressor of cell growth, is a notable trans-acting gene in the GO nucleic acid binding transcription factor activity pathway. Of the four PLAGL1 target genes discovered in FHS, three replicated in DGN (S2 Table) . One notable gene in the reactome generic transcription pathway is MED24. In our MulTiXcan analysis, MED24 targeted 13 genes in FHS (FDR < 0.05) and 8/12 replicated in DGN (P < 0.05, S2 Table) . MED24 encodes mediator complex subunit 24. The mediator complex is a transcriptional coactivator complex required for the expression of almost all genes. The mediator complex is recruited by transcriptional activators or nuclear receptors to induce gene expression, possibly by interacting with RNA polymerase II and promoting the formation of a transcriptional pre-initiation complex (33) . We also found a significant enrichment of transcription factors from Ravasi et al. (24) in the 766 unique trans-acting genes discovered in FHS with FDR <0.05 (hypergeometric test P = 9.56×10 −3 ). However, the same trans-acting genes were not enriched in signaling proteins (P = 0.71).
Target genes are enriched in transcription factor binding sites. We tested MulTiXcan validated target genes for enrichment in the same pathways tested in the trans-acting gene analysis. There were 201 unique target genes at FDR < 0.05 in FHS and P < 0.05 in DGN (S2 Table) . While just eight pathways were enriched in trans-acting genes, 118 pathways were enriched in the target genes (S4 Table) . Two of these 118 target gene enriched pathways were transcription factor binding sites (Table 3) . No binding motifs were enriched in the trans-acting genes. Additional pathways enriched in target genes included several platelet activation and immune response pathways (S4 Table) . Target genes were spread across multiple chromosomes (S2 Figure) . The target genes were not enriched for reactome generic transcription or GO nucleic acid binding transcription factor activity pathways. The 945 unique target genes discovered in FHS with FDR <0.05 were also not enriched for transcription factors (hypergeometric test P = 0.98) or signaling proteins (P = 0.46) from Ravasi et al. (24) .
Trans-acting genes are more likely to associate with complex traits. Using height as a representative complex trait, we compared PrediXcan results among three classes of gene: trans-acting, target, and background genes. transacting and target genes were those discovered in our FHS MultiXcan analysis (FDR < 0.05). Background genes are those tested in MulTiXcan, but not found significant. We examined QQ plots of PrediXcan results for each class in two large studies of height and found that trans-acting gene associations are more significant than background gene associations in both the GIANT Consortium and UK Biobank ( Fig.  5 ). Though attenuated in comparison to trans-acting genes, target genes are also more significant than background genes for association with height ( Fig. 5 ).
Discussion
We apply the PrediXcan framework to gene expression as a trait (trans-PrediXcan approach) to identify trans-acting genes that potentially regulate target genes on other chromosomes. We identify replicable predicted gene expression and observed gene expression correlations between genes on different chromosomes. Compared to trans-eQTL studies performed in the same cohorts, our trans-PrediXcan model shows a higher replication rate for discovered associations. For example, using the GTEx whole blood prediction model we show the expected true positive rate is 0.72 (Table 1) . When we performed a traditional trans-eQTL study and examined the P-value distribution of top FHS eQTLs (FDR < 0.05) in DGN, the true positive rate was only 0.46. In an independent analysis of the same data, only 4% of eQTLs discovered in FHS replicated in DGN (7).
When predictive models built in 44 different tissues are combined with MulTiXcan, we increase the number of transacting gene pairs identified in FHS and replicated in DGN 20fold compared to single-tissue models ( Table 1 ). The SNPs used to predict expression of each gene are all within 1Mb of the gene, i.e. in cis. Previous work has shown that cis-eQTLs are often shared across many tissues (5) . Thus, we show combining cis-acting effects across tissues as "replicate experiments" increases our power to detect trans-acting associations. Our approach can detect false positives due to linkage disequilibrium and thus colocalization and functional studies is required to reveal the causal trans-acting regulator of gene expression.
We found trans-acting genes discovered in our MulTiXcan analysis were enriched in transcription pathways and thus previously known to function in transcription regulation. Master regulators revealed by MulTiXcan, ARHGEF3 and AP2B1, were also previously known (30, 32) .
In contrast to our results, a recent study concluded trans-eQTLs have limited influence on complex trait biology (34) . However, the authors mention limited power in their analyses and found most of the trans-eQTLs examined were not also cis-eQTLs for nearby genes (34) . To combat lack of power, others have used cis-mediation analysis to identify trans-eQTLs (30, 35) . Similar to our approach, a mechanism is built in to significant associations found via cismediation studies: the cis-acting locus causes variable expression of the local gene, which in turn leads to variable expression of its target gene on a different chromosome. Unlike cis-mediation analysis, our trans-PrediXcan approach allows multiple SNPs to work together to affect expression of the trans-acting gene and thus may reveal additional associations. A similar method, developed in parallel to ours, combines cis-region SNPs using a cross-validation BLUP to identify trans-acting genes within one eQTL cohort (36) . Our findings have the advantage of discovery in a larger cohort, multiple tissue integration, and replication in an independent cohort.
Our transcriptome association scan presented here integrates gene expression prediction models from multiple tissues and validates results in an independent cohort. Encouragingly, the trans-acting and target genes we identify are enriched in transcription and transcription factor pathways.
Using height as a representative complex trait, trans-acting gene PrediXcan associations with height are more significant than target and background gene associations in both UK Biobank and the GIANT Consortium. This suggests percolating effects of trans-acting genes through target genes. We make our scripts and summary statistics available for future studies of trans-acting gene regulation at https: //github.com/WheelerLab/trans-PrediXcan. 
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